Affinity Improvement of a Humanized Antiviral Antibody by Structure-Based Computational Design
- 131 Downloads
Acquired immune deficiency syndrome (AIDS) is one of the most lethal infectious diseases influencing human community. While fusion of HIV-1 and host cell membranes, viral envelope glycoprotein gp120 is dissociated and a cascade of refolding events is initiated in the viral fusion protein gp41. To promote formation of the co-receptor binding site on the gp120 and initial attachment, HIV-1 employs CD4 as its primary receptor. Ibalizumab, a humanized, anti-CD4 monoclonal antibody for HIV-1 infection, was investigated in silico to design a potential improved antibody. Computer-aided antibody engineering has been successful in the design of new biologics for disease diagnosis and therapeutic interventions. Here, crystal structure of CD4 along with monoclonal antibody Ibalizumab was explored. Thr30, Ser31, Asn52, Tyr53, Asn98 and Tyr99 in heavy chain of Ibalizumab were mutated with 19 standard amino acid residues using computational methods. A set of 720 mutant macromolecules were designed, and binding affinity of these macromolecules to CD4 was evaluated through Ag-Ab docking, binding free-energy calculations, and hydrogen binding estimation. In comparison to Ibalizumab, seven designed theoretical antibody demonstrated better result in all assessments. Therefore, these newly designed macromolecules were proposed as potential antibodies to serve as therapeutic options for HIV infection.
KeywordsComputer-aided antibody engineering Affinity improvement Ibalizumab
Compliance with Ethical Standards
Conflict of interest
Tayebeh Farhadi, Atefeh Fakharian and Seyed MohammadReza Hashemian declare that they have no conflict of interest.
Research involving with Human and Animal Rights
This article does not contain any studies with human or animal subject performed by the author.
- DeLano WL (2002) The PyMOL molecular graphics system. DeLano Scientific, San CarlosGoogle Scholar
- Dimitrov A (2007) Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr Opin Investig Drugs 8:653–661Google Scholar
- Hagihara Y, Saerens D (2012) Improvement of single domain antibody stability by disulfide bond introduction. Methods Mol Biol 911:399–416Google Scholar
- Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST (2009) Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti- CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 53:450–457CrossRefGoogle Scholar
- Marvin JS, Lowman HB (2003) Redesigning an antibody fragment for faster association with its antigen. Biochemistry 42(23):7077–7083Google Scholar
- Rosok BI, Bostad L, Voltersvik P, Bjerknes R, Olofsson J, Asjo B et al (1996) Reduced CD4 cell counts in blood do not reflect CD4 cell depletion in tonsillar tissue in asymptomatic HIV-1 infection. AIDS 10(10):F35–F38Google Scholar